Advances in pharmacotherapy for treating female sexual dysfunction

Bibliography

• Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2010;7:314-26
   PubMed Web of Science ®Google Scholar
• Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7:3572-88
   PubMed Web of Science ®Google Scholar
• Nappi RE, Domoney C. Pharmacogenomics and sexuality: a vision. Climacteric 2013;16(Suppl 1):25-30
   PubMed Web of Science ®Google Scholar
• McCabe M, Althof SE, Assalian P, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2010;7:327-36
   PubMed Web of Science ®Google Scholar
• Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 2010;7:1598-607
   PubMed Web of Science ®Google Scholar
• Wylie KR. Female sexual dysfunction: reality or disease-mongering? Br J Hosp Med (Lond) 2010;71:426-7
   PubMedGoogle Scholar
• Porst H, Vardi Y, Akkus E, et al. Standards for clinical trials in male sexual dysfunctions. J Sex Med 2010;7:414-14
   PubMed Web of Science ®Google Scholar
• Clayton AH, Dennerstein L, Fisher WA, et al. Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. J Sex Med 2010;7:541-60
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3-9
   PubMed Web of Science ®Google Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124:1147-56
   PubMed Web of Science ®Google Scholar
• Cui Y, Zong H, Yan H, et al. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014;11:487-97
   PubMed Web of Science ®Google Scholar
• Goldstein I. Effect of food and drug administration decisions on sexual medicine research. J Sex Med 2014;11:2623-4
   PubMed Web of Science ®Google Scholar
• Bachmann G. Female sexuality and sexual dysfunction: are we stuck on the learning curve? J Sex Med 2006;3:639-45
   PubMed Web of Science ®Google Scholar
• Brandenburg U, Bitzer J. The challenge of talking about sex: the importance of patient-physician interaction. Maturitas 2009;63:124-7
   PubMed Web of Science ®Google Scholar
• Sobecki JN, Curlin FA, Rasinski KA, Lindau ST. What we don’t talk about when we don’t talk about sex: results of a national survey of U.S. obstetrician/gynecologists. J Sex Med 2012;9:1285-94
   PubMed Web of Science ®Google Scholar
• Biddle AK, West SL, D’Aloisio AA, et al. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health 2009;12:763-72
   PubMed Web of Science ®Google Scholar
• Basson R, Leiblum S, Brotto L, et al. Revised definitions of women’s sexual dysfunction. J Sex Med 2004;1:24-39
   PubMed Web of Science ®Google Scholar
• Brotto LA, Bitzer J, Laan E, et al. Women’s sexual desire and arousal disorders. J Sex Med 2010;7:586-614
   PubMed Web of Science ®Google Scholar
• Bitzer J, Giraldi A, Pfaus J. Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1). J Sex Med 2013;10:36-49
   PubMed Web of Science ®Google Scholar
• van Lankveld JJ, Granot M, Weijmar Schultz WC, et al. Women’s sexual pain disorders. J Sex Med 2010;7:615-31
   PubMed Web of Science ®Google Scholar
• Latif EZ, Diamond MP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril 2013;100:898-904
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Highlights of changes from DSM-IV-TR to DSM-5. American Psychiatric Press; Washington, DC: 2013
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition – text revision (DSM-IV-TR). American Psychiatric Press; Washington, DC: 2000
   Google Scholar
• Bancroft J. The medicalization of female sexual dysfunction: the need for caution. Arch Sex Behav 2002;3:451-5
   Google Scholar
• Hayes RD, Bennett CM, Fairley CK, Dennerstein L. What can prevalence studies tell us about female sexual difficulty and dysfunction? J Sex Med 2006;3:589-95
   PubMed Web of Science ®Google Scholar
• Sand M, Fisher WA. Women’s endorsement of models of female sexual response: the nurses’ sexuality study. J Sex Med 2007;4:708-19
   PubMed Web of Science ®Google Scholar
• Carvalheira AA, Brotto LA, Leal I. Women’s motivations for sex: exploring the diagnostic and statistical manual, fourth edition, text revision criteria for hypoactive sexual desire and female sexual arousal disorders. J Sex Med 2010;7:1454-63
   PubMed Web of Science ®Google Scholar
• Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet 2007;369:409-24
   PubMed Web of Science ®Google Scholar
• Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970-8
   PubMed Web of Science ®Google Scholar
• Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the “true” prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? J Sex Med 2008;5:777-87
   PubMed Web of Science ®Google Scholar
• Buster JE. Managing female sexual dysfunction. Fertil Steril 2013;100:905-15
   PubMed Web of Science ®Google Scholar
• Nappi R, Salonia A, Traish AM, et al. Clinical biologic pathophysiologies of women’s sexual dysfunction. J Sex Med 2005;2:4-25
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Bitzer J, Brandenburg U, et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric 2010;13:103-20
   PubMed Web of Science ®Google Scholar
• Bitzer J, Giraldi A, Pfaus J. A standardized diagnostic interview for hypoactive sexual desire disorder in women: standard operating procedure (SOP Part 2). J Sex Med 2013;10:50-7
   PubMed Web of Science ®Google Scholar
• Fugl-Meyer KS, Bohm-Starke N, Damsted Petersen C, et al. Standard operating procedures for female genital sexual pain. J Sex Med 2013;10:83-93
   PubMed Web of Science ®Google Scholar
• Laan E, Rellini AH, Barnes T; International Society for Sexual Medicine. Standard operating procedures for female orgasmic disorder: consensus of the International Society for Sexual Medicine. J Sex Med 2013;10:74-82
   PubMed Web of Science ®Google Scholar
• Kingsberg SA. Attitudinal survey of women living with low sexual desire. J Womens Health (Larchmt) 2014;23:817-23
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013;10:2232-41
   PubMed Web of Science ®Google Scholar
• Woloski-Wruble AC, Oliel Y, Leefsma M, Hochner-Celnikier D. Sexual activities, sexual and life satisfaction, and successful aging in women. J Sex Med 2010;7:2401-10
   PubMed Web of Science ®Google Scholar
• Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-74
   PubMed Web of Science ®Google Scholar
• Schneidewind-Skibbe A, Hayes RD, Koochaki PE, et al. The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions. J Sex Med 2008;5:301-35
   PubMed Web of Science ®Google Scholar
• Hayes RD, Dennerstein L, Bennett CM, et al. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril 2007;87:107-12
   PubMed Web of Science ®Google Scholar
• Rosen RC, Shifren JL, Monz BU, et al. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6:1549-60
   PubMed Web of Science ®Google Scholar
• Berry MD, Berry PD. Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model. J Sex Med 2013;10:2627-43
   PubMed Web of Science ®Google Scholar
• Nappi RE, Polatti F. The use of estrogen therapy in women’s sexual functioning. J Sex Med 2009;6:603-16
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martini E, Terreno E, et al. Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Womens Health 2010;2:167-75
   PubMedGoogle Scholar
• Wierman ME, Nappi RE, Avis N, et al. Endocrine aspects of women’s sexual function. J Sex Med 2010;7:561-85
   PubMed Web of Science ®Google Scholar
• Basson R. Pharmacotherapy for women’s sexual dysfunction. Expert Opin Pharmacother 2009;10:1631-48
   PubMed Web of Science ®Google Scholar
• Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother 2012;13:2131-42
   PubMed Web of Science ®Google Scholar
• Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012;9:1134-48
   PubMed Web of Science ®Google Scholar
• Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15:267-74
   PubMed Web of Science ®Google Scholar
• DeGregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids 2014;90:82-93
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282-8
   PubMed Web of Science ®Google Scholar
• Chivers ML, Rosen RC. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? J Sex Med 2010;7:858-72
   PubMed Web of Science ®Google Scholar
• Poels S, Bloemers J, van Rooij K, et al. Two novel combined drug treatments for women with hypoactive sexual desire disorder. Pharmacol Biochem Behav 2014;121:71-9
   PubMed Web of Science ®Google Scholar
• Thorp JJr, Palacios S, Symons J, et al. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG 2014;121:1328-31
   PubMed Web of Science ®Google Scholar
• Ückert S, Bannowsky A, Albrecht K, Kuczyk MA. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opin Investig Drugs 2014;23:1477-83
   PubMed Web of Science ®Google Scholar
• Belkin ZR, Krapf JM, Goldstein AT. Drugs in early clinical development for the treatment of female sexual dysfunction. Expert Opin Investig Drugs 2015;24(2):159-67
   PubMed Web of Science ®Google Scholar
• Fooladi E, Bell RJ, Davis SR. Management strategies in SSRI-associated sexual dysfunction in women at midlife. Climacteric 2012;15:306-16
   PubMed Web of Science ®Google Scholar
• Leo RJ, Dewani S. A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med 2013;10:2497-505
   PubMedGoogle Scholar
• Davis SR, Worsley R. Androgen treatment of postmenopausal women. J Steroid Biochem Mol Biol 2014;142:107-14
   PubMed Web of Science ®Google Scholar
• Shamloul R. Natural aphrodisiacs. J Sex Med 2010;7:39-49
   PubMed Web of Science ®Google Scholar
• Burnett AL, Goldstein I, Andersson KE, et al. Future sexual medicine physiological treatment targets. J Sex Med 2010;7:3269-304
   PubMed Web of Science ®Google Scholar
• Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-33
   PubMed Web of Science ®Google Scholar
• Munarriz R, Kim NN, Goldstein I, Traish AM. Biology of female sexual function. Urol Clin North Am 2002;29:685-93
   PubMed Web of Science ®Google Scholar
• Giraldi A, Marson L, Nappi R, et al. Physiology of female sexual function: animal models. J Sex Med 2004;1:237-53
   PubMed Web of Science ®Google Scholar
• Salonia A, Giraldi A, Chivers ML, et al. Physiology of women’s sexual function: basic knowledge and new findings. J Sex Med 2010;7:2637-60
   PubMed Web of Science ®Google Scholar
• Basson R. Testosterone therapy for reduced libido in women. Ther Adv Endocrinol Metab 2010;1:155-64
   PubMedGoogle Scholar
• Kingsberg SA, Althof SE. Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction. J Sex Med 2011;8:3262-70
   PubMed Web of Science ®Google Scholar
• Bradford A. Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med 2013;10:451-9
   PubMed Web of Science ®Google Scholar
• Nappi RE. New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric 2007;10(Suppl 2):105-8
   PubMedGoogle Scholar
• Levine K, Williams R, Harmann K. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661-6
   PubMed Web of Science ®Google Scholar
• Nappi RE, Lello S, Melis GB, et al. LEI (Lack of tEstosterone Impact) survey in a clinical sample with surgical menopause. Climacteric 2009;12:533-40
   PubMed Web of Science ®Google Scholar
• Davis SR. Androgen therapy in women, beyond libido. Climacteric 2013;16(Suppl 1):18-24
   PubMedGoogle Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316-37
   PubMed Web of Science ®Google Scholar
• Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2013;6:CD009672
   Google Scholar
• Alexander JL, Kotz K, Dennerstein L, et al. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause 2004;11:749-65
   PubMed Web of Science ®Google Scholar
• Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecol Endocrinol 2010;26:804-14
   PubMed Web of Science ®Google Scholar
• Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162-70
   PubMed Web of Science ®Google Scholar
• Nappi RE, Ferdeghini F, Sampaolo P, et al. Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy. Maturitas 2006;55:288-95
   PubMed Web of Science ®Google Scholar
• Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:28-41
   PubMedGoogle Scholar
• Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646-56
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22
   PubMed Web of Science ®Google Scholar
• Rees M, Pérez-López FR, Ceasu I, et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 2012;73:171-4
   PubMed Web of Science ®Google Scholar
• NAMS. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902
   PubMed Web of Science ®Google Scholar
• Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2014;1-14. [Epub ahead of print]
   Google Scholar
• Simon J, Nachtigall L, Gut R, et al. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-60
   PubMed Web of Science ®Google Scholar
• Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76
   PubMed Web of Science ®Google Scholar
• Cano A, Estévez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 2012;19:1130-9
   PubMed Web of Science ®Google Scholar
• Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;4):CD004509
   Google Scholar
• Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3489-510
   PubMed Web of Science ®Google Scholar
• Kingsberg S, Shifren J, Wekselman K, et al. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007;4:1001-8
   PubMed Web of Science ®Google Scholar
• Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944-52
   PubMed Web of Science ®Google Scholar
• Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33
   PubMed Web of Science ®Google Scholar
• Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006;13:770-9
   PubMed Web of Science ®Google Scholar
• Davis SR, Moreau M, Kroll R, et al. APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-17
   PubMed Web of Science ®Google Scholar
• Panay N, Al-Azzawi F, Bouchard C. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121-31
   PubMed Web of Science ®Google Scholar
• Fooladi E, Bell RJ, Jane F, et al. Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial. J Sex Med 2014;11:831-9
   PubMed Web of Science ®Google Scholar
• White WB, Grady D, Giudice LC, et al. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J 2012;163:27-32
   PubMed Web of Science ®Google Scholar
• Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 2008;148:569-77
   PubMed Web of Science ®Google Scholar
• Fernandes T, Costa-Paiva LH, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med 2014;11:1262-70
   PubMed Web of Science ®Google Scholar
• Pessina MA, Hoyt RFJr, Goldstein I, Traish AM. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology 2006;147:61-9
   PubMed Web of Science ®Google Scholar
• Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424-31
   PubMed Web of Science ®Google Scholar
• Davis SR, Goldstat R, Papalia MA, et al. Effects of aromatase inhibition on sexual function wellbeing in postmenopausal women treated with testosterone: a randomized placebo controlled trial. Menopause 2006;13:37-45
   PubMed Web of Science ®Google Scholar
• Snabes MC, Simes SM. Approved hormonal treatments for HSDD: an unmet medical need. J Sex Med 2009;6:1846-9
   PubMed Web of Science ®Google Scholar
• Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol 2015;145C:133-8
   Google Scholar
• Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011;96:1642-53
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-22
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-31
   PubMed Web of Science ®Google Scholar
• Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 2011;70:22-5
   PubMed Web of Science ®Google Scholar
• Berga SL. Profile of ospemifene in the breast. Reprod Sci 2013;20:1130-6
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene Study Group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173-82
   PubMed Web of Science ®Google Scholar
• Archer DF, Carr BR, Pinkerton JV, et al. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause 2014. [Epub ahead of print]
   Google Scholar
• Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623-30
   PubMed Web of Science ®Google Scholar
• Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91-8
   PubMed Web of Science ®Google Scholar
• Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2014;1-8. [Epub ahead of print]
   Google Scholar
• Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2014;1-7. [Epub ahead of print]
   Google Scholar
• Ågmo A. Animal models of female sexual dysfunction: basic considerations on drugs, arousal, motivation and behavior. Pharmacol Biochem Behav 2014;121:3-15
   PubMedGoogle Scholar
• Arnow BA, Millheiser L, Garrett A, et al. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 2009;158:484-502
   PubMed Web of Science ®Google Scholar
• Levin RJ. The pharmacology of the human female orgasm - its biological and physiological backgrounds. Pharmacol Biochem Behav 2014;121:62-70
   PubMed Web of Science ®Google Scholar
• Maravilla KR, Yang CC. Magnetic resonance imaging and the female sexual response: overview of techniques, results, and future directions. J Sex Med 2008;5:1559-71
   PubMed Web of Science ®Google Scholar
• Clayton AH, Dennerstein L, Pyke R, Sand M. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Womens Health (Lond Engl) 2010;6:639-53
   PubMedGoogle Scholar
• Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014;21:633-40
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Rudkin L, Bullemor-Day P, et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013;5:CD003382
   Google Scholar
• Reviriego C. Flibanserin for female sexual dysfunction. Drugs Today (Barc) 2014;50:549-56
   PubMedGoogle Scholar
• DeRogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med 2012;9:1074-85
   PubMed Web of Science ®Google Scholar
• Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012;9:793-804
   PubMed Web of Science ®Google Scholar
• Jayne C, Simon JA, Taylor LV, et al. SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med 2012;9:3180-8
   PubMed Web of Science ®Google Scholar
• Katz M, Derogatis L, Ackerman P, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013;10:1807-15
   PubMed Web of Science ®Google Scholar
• Nappi R, Dean J, van Lunsen H, et al. Efficacy of continued flibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in European pre-menopausal women: results from the ORCHID trial. J Sex Med 2009;6(Suppl 5):409
   Google Scholar
• Goldfischer E, Cotton D, Miki J, et al. Efficacy of continued flibanserin treatment on sexual desire and satisfying sexual events in premenopausal women with Hypoactive Sexual Desire Disorder: results from the ROSE study. J Sex Med 2008;5(Suppl 3):174
   Google Scholar
• Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. Pharmacotherapy 2013;33:411-21
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Hosseini SY, Asgari MA, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int 2010;106:832-9
   PubMedGoogle Scholar
• Clayton AH, El Haddad S, Iluonakhamhe JP, et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf 2014;13:1361-74
   PubMed Web of Science ®Google Scholar
• Caruso S, Agnello C, Intelisano G, et al. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 2004;63:955-9
   PubMed Web of Science ®Google Scholar
• Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med 2007;4(Suppl 4):269-79
   PubMedGoogle Scholar
• Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med 2008;5:887-97
   PubMed Web of Science ®Google Scholar
• Portman DJ, Edelson J, Jordan R, et al. Bremelanotide for hypoactive sexual desire disorder: analyses from a phase 2B dose-ranging study. Obstet Gynecol 2014;123(Suppl 1):31S
   Google Scholar
• Derogatis LR, Edelson J, Jordan R, et al. Bremelanotide for female sexual dysfunctions: responder analyses from a phase 2B dose-ranging study. Obstet Gynecol 2014;123(Suppl 1):26S
   Google Scholar
• Kingsberg S, Derogatis LR, Edelson J, et al. Distress reduction in female sexual dysfunctions: a dose-ranging study of subcutaneous bremelanotide. Obstet Gynecol 2014;123(Suppl 1):29S-30S
   PubMedGoogle Scholar
• Caruso S, Rugolo S, Agnello C, et al. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006;85:1496-501
   PubMed Web of Science ®Google Scholar
• Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000;55:812-15
   PubMed Web of Science ®Google Scholar
• Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004;171:1189-93
   PubMed Web of Science ®Google Scholar
• Nurnberg HG, Hensley PL, Heiman JR, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300:395-404
   PubMed Web of Science ®Google Scholar
• Schoen C, Bachmann G. Sildenafil citrate for female sexual arousal disorder: a future possibility? Nat Rev Urol 2009;6:216-22
   PubMed Web of Science ®Google Scholar
• Rosen RC, Phillips NA, Gendrano NCIII, Ferguson DM. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther 1999;25:137-44
   PubMed Web of Science ®Google Scholar
• Kielbasa LA, Daniel KL. Topical alprostadil treatment of female sexual arousal disorder. Ann Pharmacother 2006;40:1369-76
   PubMed Web of Science ®Google Scholar
• Behnia B, Heinrichs M, Bergmann W, et al. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Horm Behav 2014;65:308-18
   PubMed Web of Science ®Google Scholar
• Bloemers J, van Rooij K, Poels S, et al. Toward personalized sexual medicine (part 1): integrating the “dual control model” into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. J Sex Med 2013;10:791-809
   PubMed Web of Science ®Google Scholar
• Tuiten A, van Honk J, Verbaten R, et al. Can sublingual testosterone increase subjective and physiological measures of laboratory-induced sexual arousal? Arch Gen Psychiatry 2002;59:465-6
   PubMedGoogle Scholar
• Poels S, Bloemers J, van Rooij K, et al. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. J Sex Med 2013;10:810-23
   PubMed Web of Science ®Google Scholar
• van Rooij K, Poels S, Bloemers J, et al. Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. J Sex Med 2013;10:824-37
   PubMed Web of Science ®Google Scholar
• van Rooij K, Poels S, Worst P, et al. Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study. Eur J Pharmacol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• van der Made F, Bloemers J, Yassem WE, et al. The influence of testosterone combined with a PDE5- inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med 2009;6:777-90
   PubMed Web of Science ®Google Scholar
• Leusink P, Boeke AJ, Laan E. Toward personalized sexual medicine: where is the evidence? J Sex Med 2014;11:2357-8
   PubMedGoogle Scholar
• Tuiten A, Bloemers J, van Rooij K, et al. Response to “toward personalized sexual medicine: where is the evidence?”. J Sex Med 2014;11:2359-63
   PubMedGoogle Scholar